Biotech & Pharma AI: RAG Implementation for Literature, Regulations, and Clinical Trial Data

A generic drug company came to us with a change control registration across three markets. The regulatory affairs manager dropped a stack of documents on the desk and described the situation: finding the current impurity limits for each market took two people three days. It wasn't a matter of lacking expertise. The information was scattered across ICH guidelines, pharmacopeias from different countries, internal CMC reports, and agency review letters from five years back. No one person could retain all of it, and every document had different versions, expiration dates, and scopes of application.

The pain in biotech and pharma is clear: too much information spread too thin and impossible to trace back to the source.

Biotech and pharma AI: laying out evidence, not making decisions

Biotech and pharma AI connects a large language model to literature, regulations, and clinical trial data so that R&D and regulatory teams can ask questions in plain language and receive answers where every sentence is tagged with its original source. The model itself makes no clinical or regulatory judgments. It retrieves traceable evidence, consolidates it, and presents it to the person making the decision.

In this industry, a statement without a source has no value. AI-generated text that points to no specific guideline section cannot support a document for regulatory review. When building biotech and pharma AI, the first priority is not polished answers. Every conclusion must trace back to the source page and specific section.

RAG is the only architecture that makes sense here

RAG (retrieval-augmented generation) is preferable to querying a general-purpose model or fine-tuning a large language model for three central reasons.

Regulations and literature evolve quickly. When ICH publishes a revision, FDA releases new guidance, or a clinical endpoint updates for some indication, a fine-tuned model becomes obsolete instantly. RAG requires only dropping the new document into the knowledge base for immediate queryability. Hallucination is an unacceptable cost in this industry. RAG forces the model to answer only based on retrieved passages. If the model cannot find an answer, it says so instead of inventing something that sounds plausible, like an impurity limit. Access control is the third reason, often overlooked. In the same system, the team working on Product A should not see unpublished clinical data from Product B. RAG's retrieval layer is the natural place to enforce permissions.

In practice, the system splits into three data sources, each mapped to what a different team member actually does:

Separate indexes for each exist because they update at different rates, have different sensitivity levels, and use completely different citation formats. Clinical trial data is especially sensitive. It is filtered at the retrieval layer by project and by role, so the model never sees passages it should not access. Masking information after generation arrives too late. The data is already in the prompt by then.

A real before-and-after

Before implementation, comparing impurity limits across three markets required two people working three days. Results still needed review by a senior manager because no one could guarantee nothing was missed. After implementation, the same question asked in plain language returns each market's current requirements in forty seconds, with each linked to the guideline version and section. The manager clicks through to verify sources instead of re-checking everything. Review time shifted from starting over completely to verifying citations.

Version one merged all three data sources into one large index. The model kept using numbers from clinical reports to answer regulatory questions, mixing different contexts. Splitting them apart stabilized the system. PDF chunking appears to be a small detail but determines success or failure. When a regulatory table is cut incorrectly, the impurity number becomes detached from its conditions, and answers become dangerous. Specialized parsing for tables and regulatory sections eventually replaced generic chunking. These details do not appear in demos. They cause problems in week three of production.

Usage was initially low because regulatory teams did not trust the system. Professional training teaches skepticism toward anything without a source. The shift came when citations became clickable. One click led to the exact page with that section highlighted. When verification proved faster than manually searching documents, teams started using the system.

What actually determines success with biotech and pharma AI

Success or failure depends on how data is structured, how access controls are implemented, how citations are restored, and whether the system integrates into the daily workflows of regulatory affairs and R&D teams. Engineers work on-site with customers, alongside regulatory and R&D staff, carrying the system from build to launch to daily use. The test is not audience agreement at the demo. The test is whether, three months later, that manager uses it to review documents submitted for approval.